Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies
February 22, 2019 08:00 ET
|
Voyager Therapeutics, Inc.
Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein Voyager to receive $65 million upfront and up to $245 million in preclinical and Phase 1...
Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
March 14, 2018 07:02 ET
|
Voyager Therapeutics, Inc.
VY-AADC for advanced Parkinson’s disease on track for start of planned global, pivotal Phase 2-3 program during the middle of this year Two IND filings expected from the ALS, Huntington’s disease and...
Voyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson’s Disease
March 09, 2018 07:02 ET
|
Voyager Therapeutics, Inc.
Robust and durable improvements in patients' motor function achieved with substantial reductions in use of daily oral levodopa and other Parkinson’s disease medications; one-time administrations of...
Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases
February 20, 2018 07:00 ET
|
Voyager Therapeutics, Inc.
Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau Voyager to receive $69 million upfront payment and...
Voyager Therapeutics Announces CEO Succession Plan for 2018
January 31, 2018 16:05 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Announces FDA Clearance of Investigational New Drug Application for VY-AADC for Advanced Parkinson’s Disease
January 23, 2018 07:04 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Highlights Lead Program VY-AADC for Advanced Parkinson’s Disease, AAV Novel Capsid and Delivery Optimization Efforts, and Pipeline Programs at its R&D Day
November 16, 2017 16:45 ET
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Highlights
November 02, 2017 16:01 ET
|
Voyager Therapeutics, Inc.
VY-AADC for advanced Parkinson’s disease on track for start of global, pivotal phase 2-3 program Integration of novel capsid and delivery optimization efforts expected to result in two IND filings...
Voyager Therapeutics Announces Update to Parkinson’s Disease Program
October 30, 2017 16:01 ET
|
Voyager Therapeutics, Inc.
Voyager to gain worldwide rights to VY-AADC program for advanced Parkinson’s disease Global, pivotal Phase 2-3 program for VY-AADC on track to dose the first patient during the second quarter of 2018...
Voyager Therapeutics Announces New Data Presentations at the Congress of the European Society of Gene and Cell Therapy
October 17, 2017 03:00 ET
|
Voyager Therapeutics, Inc.
New data with novel AAV gene therapy capsids demonstrate widespread gene transfer to the brain and spinal cord of non-human primates after a single intravenous administration Additional studies at...